About 64,418 results

ALLMedicine™ Hepatocellular Carcinoma Center

Research & Reviews  23,807 results

Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver F...
Journal of Hepatocellular Carcinoma; Zhao D, Zhang X et. al.

May 21st, 2022 - The aim of this study was to identify and validate novel biomarkers for distinguishing among hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), liver fibrosis/liver cirrhosis (LF/LC) and chronic hepatitis B (CHB). Transcriptomic seque...

RNA Binding Motif Protein 3 Promotes Cell Metastasis and Epithelial-Mesenchymal Transit...
Journal of Hepatocellular Carcinoma; Zhang L, Zhang Y et. al.

May 21st, 2022 - RNA binding motif protein 3 (RBM3) has been reported to be dysregulated in various cancers and associated with tumor aggressiveness. Epithelial-mesenchymal transition (EMT) is an important biological process by which tumor cells acquire metastatic...

PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlate...
Disease Markers; Wang Z, Rehman AU et. al.

May 21st, 2022 - The dysregulated PI3K/AKT/mTOR pathway acts as the main regulator of tumorigenesis in hepatocellular carcinoma (HCC). Here, we identify the prognostic significance of PI3K/AKT/mTOR pathway-associated genes (PAGs) as well as their putative signatur...

P2X4 receptors mediate induction of antioxidants, fibrogenic cytokines and ECM transcri...
PloS One; Manzoor S, Khalid M et. al.

May 21st, 2022 - Major HCV infections lead to chronic hepatitis, which results in progressive liver disease including fibrosis, cirrhosis and eventually hepatocellular carcinoma (HCC). P2X4 and P2X7 are most widely distributed receptors on hepatocytes. Full length...

see more →

Guidelines  35 results

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Gastroenterology Su GL, Altayar O et. al.

Feb 26th, 2022 - Hepatocellular carcinoma (HCC), the most common primary liver cancer, remains a deadly cancer, with an incidence that has tripled in the United States since 1980. In recent years, new systemic therapies for HCC have been approved and a critical as...

Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the ...
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; , et. al.

Dec 21st, 2021 - Nonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes, and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the last years,...

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice G...
Practical Radiation Oncology; Apisarnthanarax S, Barry A et. al.

Oct 25th, 2021 - This guideline provides evidence-based recommendations for the indications and technique-dose of external beam radiation therapy (EBRT) in hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC). The American Society for Radiation...

Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
Clinics and Research in Hepatology and Gastroenterology; Tran A, Shili-Masmoudi S et. al.

Aug 1st, 2021 - Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Clinical care for patients with HCV-related liver disease has advanced considerably with developments in screening, diagnostic procedures to evaluate liver fibrosis and i...

Non-invasive diagnosis and follow-up in liver transplantation.
Clinics and Research in Hepatology and Gastroenterology; Dumortier J, Besch C et. al.

Aug 1st, 2021 - The field of liver transplantation directly or indirectly embodies all liver diseases, in addition to specific ones related to organ rejection (cellular and humoral). The recommended non-invasive methods for determining the indication for liver tr...

see more →

Drugs  19 results see all →

Clinicaltrials.gov  678 results

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

May 20th, 2022 - Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second leading cause of cancer-associated mortality with an average life expectancy of 6-9 months Despite the success of several studies showing efficacy ...

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

May 20th, 2022 - This is a randomized, double-blind, placebo-controlled, multicenter, global Phase III study to determine the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE given with durv...

LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment With Transarterial Embolization (TAE) Alone or Combined With Thermal Ablation

May 20th, 2022 - Background: Hepatocellular Carcinoma (HCC) is the 3rd most common cause of cancer globally with an increasing incidence worldwide. Management of hepatic malignancies from primary Hepatocellular Carcinoma (HCC) or metastatic disease involves a mult...

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

May 20th, 2022 - The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without ...

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

May 18th, 2022 - This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or ...

see more →

News  1,224 results

TIPS plus sequential systemic therapy shows promise in advanced HCC with tumor thrombus-related SPH

May 17th, 2022 - Key clinical point: Transjugular intrahepatic portosystemic shunt (TIPS) plus sequential systemic therapy is safe and feasible for treating portal vein tumor thrombus (PVTT)-related symptomatic portal hypertension (SPH) in advanced hepatocellular.

HCC incidence after successful DAA therapy for hepatitis C varies with cirrhosis status

May 17th, 2022 - Key clinical point: Among patients with hepatitis C virus (HCV) who achieved a sustained virologic response (SVR) after direct-acting antiviral (DAA) therapy, those with cirrhosis showed an extremely high incidence of hepatocellular carcinoma (HCC.

Laparoscopic anatomic hepatectomy achieves better follow-up outcomes than non-anatomical hepatectomy in HCC

May 17th, 2022 - Key clinical point: As laparoscopic anatomical hepatectomy (LAH) is associated with increased disease-free survival (DFS) and comparable long-term overall survival (OS) and postoperative complications compared with non-anatomical hepatectomy (LNAH.

Does imaging surveillance intensity govern clinical outcomes in HCC?

May 17th, 2022 - Key clinical point: Compared with the standard ultrasonography (US)-based imaging surveillance for hepatocellular carcinoma (HCC), intensive surveillance using alternative computed tomography (CT)/magnetic resonance imaging (MRI) in addition to US.

Deep learning system outmatches pathologists in diagnosing liver lesions
Will Pass

May 4th, 2022 - A new deep learning system can classify hepatocellular nodular lesions (HNLs) via whole-slide images, improving risk stratification of patients and diagnostic rate of hepatocellular carcinoma (HCC), according to investigators. While the model requ.

see more →

Patient Education  4 results see all →